Literature DB >> 17617518

Role of surgery in ovarian carcinoma.

Amanda Nickles Fader1, Peter G Rose.   

Abstract

Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early- or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from other metastatic solid tumors is that surgical cytoreduction of tumor volume is highly correlated with prolongation of patient survival. Procedures such as radical pelvic surgery, bowel resection, and aggressive upper abdominal surgery are commonly required to achieve optimal cytoreduction. Women who develop recurrent disease may be eligible for a secondary cytoreductive surgery or may require a surgical intervention to palliate disease-related symptoms. For women at high risk of ovarian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this disease. The purpose of this article is to provide a comprehensive review of the surgical management of ovarian carcinoma. The roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and palliative surgery are reviewed. The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed.

Entities:  

Mesh:

Year:  2007        PMID: 17617518     DOI: 10.1200/JCO.2007.11.0932

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  46 in total

1.  Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy.

Authors:  Joseph Menczer; Angela Chetrit; Siegal Sadetzki
Journal:  J Gynecol Oncol       Date:  2010-09-28       Impact factor: 4.401

2.  Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.

Authors:  Sarah A Ackroyd; Sajeena Thomas; Cynthia Angel; Richard Moore; Philip J Meacham; Brent DuBeshter
Journal:  J Robot Surg       Date:  2017-06-19

Review 3.  Gynecologic cancer disparities: a report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.

Authors:  Yvonne Collins; Kevin Holcomb; Eloise Chapman-Davis; Dineo Khabele; John H Farley
Journal:  Gynecol Oncol       Date:  2014-01-07       Impact factor: 5.482

Review 4.  Latest research and treatment of advanced-stage epithelial ovarian cancer.

Authors:  Robert L Coleman; Bradley J Monk; Anil K Sood; Thomas J Herzog
Journal:  Nat Rev Clin Oncol       Date:  2013-02-05       Impact factor: 66.675

5.  Ovarian metastasis from pulmonary adenocarcinoma.

Authors:  Young-Eun Jung; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  Obstet Gynecol Sci       Date:  2013-09-14

6.  Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Peter G Rose; James J Java; Mark A Morgan; Angeles Alvarez-Secord; Joshua P Kesterson; Frederick B Stehman; David P Warshal; William T Creasman; Parviz Hanjani; Robert T Morris; Larry J Copeland
Journal:  Gynecol Oncol       Date:  2016-09-28       Impact factor: 5.482

Review 7.  Treatment of the primary tumor in metastatic prostate cancer.

Authors:  Ye Yuan; Amar U Kishan; Nicholas G Nickols
Journal:  World J Urol       Date:  2018-11-19       Impact factor: 4.226

8.  PIK3CA alterations in Middle Eastern ovarian cancers.

Authors:  Jehad Abubaker; Prashant Bavi; Wael Al-Haqawi; Zeenath Jehan; Adnan Munkarah; Shahab Uddin; Khawla S Al-Kuraya
Journal:  Mol Cancer       Date:  2009-07-28       Impact factor: 27.401

9.  The utility and cost of routine follow-up procedures in the surveillance of ovarian and primary peritoneal carcinoma: a 16-year institutional review.

Authors:  N B Rettenmaier; C R Rettenmaier; T Wojciechowski; L N Abaid; J V Brown; J P Micha; B H Goldstein
Journal:  Br J Cancer       Date:  2010-11-02       Impact factor: 7.640

10.  Role of CT scan-based and clinical evaluation in the preoperative prediction of optimal cytoreduction in advanced ovarian cancer: a prospective trial.

Authors:  G Ferrandina; G Sallustio; A Fagotti; G Vizzielli; A Paglia; E Cucci; A Margariti; L Aquilani; G Garganese; G Scambia
Journal:  Br J Cancer       Date:  2009-09-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.